Notably, the oral administration of CX-4945 dramatically suppressed the phosphorylation of Tau in the hippocampus of DS-like mice within 30 min (Fig. 7), demonstrating its efficient penetrability through the BBB and DYRK1A-inhibitory activity in a higher-animal model. Here, DYRK1A is linked to Dravet syndrome.